NCT02520518View on ClinicalTrials.gov

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Weight Loss
Interventions
DRUG

Dapagliflozin

DRUG

Placebo

BEHAVIORAL

Weight maintenance

BEHAVIORAL

Ad libitum dietary intake

BEHAVIORAL

Dietary restriction

Trial Locations (1)

80523-1582

Colorado State University, Dept. of Health and Exercise Science, Fort Collins

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Christopher Bell

OTHER